The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aη, including Alzheimers disease, Downs syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.